关于“转移性黑色素瘤的进展与新型治疗选择”特刊的社论
Editorial on Special Issue "Advances and Novel Treatment Options in Metastatic Melanoma".
作者信息
Carè Alessandra, Del Bufalo Donatella, Facchiano Antonio
机构信息
Center for Gender-Specific Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
出版信息
Cancers (Basel). 2022 Jan 29;14(3):707. doi: 10.3390/cancers14030707.
Abstract
Investigating mechanisms controlling melanoma setup, development and progression is currently an extremely hot and rapidly evolving topic [...].
摘要
目前，研究控制黑色素瘤形成、发展和进展的机制是一个极其热门且快速发展的课题[...]。
相似文献
1
Editorial on Special Issue "Advances and Novel Treatment Options in Metastatic Melanoma".关于“转移性黑色素瘤的进展与新型治疗选择”特刊的社论
Cancers (Basel). 2022 Jan 29;14(3):707. doi: 10.3390/cancers14030707.
2
Editorial for Special Issue "Advances in the Pathogenesis and Treatment of Immune-Mediated Inflammatory Diseases".专刊编辑寄语：免疫介导的炎症性疾病发病机制和治疗的研究进展
Int J Mol Sci. 2022 Jul 29;23(15):8415. doi: 10.3390/ijms23158415.
3
Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease.新型治疗时代转移性黑色素瘤的治疗选择：皮肤科医生实用指南：第一部分：III 期疾病的治疗。
J Am Acad Dermatol. 2013 Jan;68(1):1.e1-9; quiz 10-12. doi: 10.1016/j.jaad.2012.09.040.
4
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.黑色素瘤研究的未来展望：“黑色素瘤桥梁”会议报告：那不勒斯，2014年12月3日至6日
J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.
5
Evolving pharmacotherapies for the treatment of metastatic melanoma.不断发展的转移性黑色素瘤治疗药物疗法。
Clin Med Insights Oncol. 2013 Jun 20;7:137-49. doi: 10.4137/CMO.S9565. Print 2013.
6
Novel therapeutics for the treatment of metastatic melanoma.用于治疗转移性黑色素瘤的新型疗法。
Future Oncol. 2009 May;5(4):543-57. doi: 10.2217/fon.09.15.
7
Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.转移性葡萄膜黑素瘤的系统性和肝脏靶向治疗：最新技术和新视角。
Future Oncol. 2021 Nov;17(33):4583-4606. doi: 10.2217/fon-2021-0318. Epub 2021 Aug 25.
8
Targeted therapies: Improved outcomes for patients with metastatic melanoma.靶向治疗：改善转移性黑色素瘤患者的预后。
Nat Rev Clin Oncol. 2011 Jul 26;8(9):513-5. doi: 10.1038/nrclinonc.2011.119.
9
Molecular mechanisms controlling human melanoma progression and metastasis.控制人类黑色素瘤进展和转移的分子机制。
Pathobiology. 1997;65(6):311-30. doi: 10.1159/000164143.
10
Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.考比替尼：抑制BRAF V600突变型黑色素瘤中的MEK1/2。
Drugs Today (Barc). 2016 Nov;52(11):593-605. doi: 10.1358/dot.2016.52.11.2542234.
引用本文的文献
1
Strong Activation of , , and Genes Is Coupled with the Formation of Vasculogenic Mimicry Phenotype in Melanoma Cells.在黑色素瘤细胞中，基因的强烈激活与血管生成拟态表型的形成相关。
Int J Mol Sci. 2024 Aug 27;25(17):9291. doi: 10.3390/ijms25179291.
2
Thinking (Metastasis) outside the (Primary Tumor) Box.突破（原发性肿瘤）局限进行思考（转移）。
Cancers (Basel). 2023 Nov 7;15(22):5315. doi: 10.3390/cancers15225315.
3
Silencing of Dicer enhances dacarbazine resistance in melanoma cells by inhibiting ADSL expression.沉默 Dicer 通过抑制 ADSL 表达增强黑色素瘤细胞对达卡巴嗪的耐药性。
Aging (Albany NY). 2023 Nov 15;15(22):12873-12889. doi: 10.18632/aging.205207.
本文引用的文献
1
Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells.HuR癌蛋白的分子靶向作用抑制MITF并诱导黑色素瘤细胞凋亡。
Cancers (Basel). 2021 Jan 6;13(2):166. doi: 10.3390/cancers13020166.
2
BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance.BCL2L10在STAT3下游的黑色素瘤中过表达，并促进顺铂和ABT-737耐药。
Cancers (Basel). 2020 Dec 30;13(1):78. doi: 10.3390/cancers13010078.
3
Investigating Serum and Tissue Expression Identified a Cytokine/Chemokine Signature as a Highly Effective Melanoma Marker.通过研究血清和组织表达确定细胞因子/趋化因子特征作为高效黑色素瘤标志物
Cancers (Basel). 2020 Dec 8;12(12):3680. doi: 10.3390/cancers12123680.
4
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects.皮肤黑色素瘤的分子和免疫生物标志物：现状与未来前景
Cancers (Basel). 2020 Nov 20;12(11):3456. doi: 10.3390/cancers12113456.
5
A Framework of Major Tumor-Promoting Signal Transduction Pathways Implicated in Melanoma-Fibroblast Dialogue.黑色素瘤-成纤维细胞对话中涉及的主要肿瘤促进信号转导通路框架
Cancers (Basel). 2020 Nov 17;12(11):3400. doi: 10.3390/cancers12113400.
6
Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma.癌症干细胞与慢循环表型：如何解开黑色素瘤中驱动治疗耐药性的死结
Cancers (Basel). 2020 Nov 13;12(11):3368. doi: 10.3390/cancers12113368.
7
ShcD Binds DOCK4, Promotes Ameboid Motility and Metastasis Dissemination, Predicting Poor Prognosis in Melanoma.ShcD与DOCK4结合，促进阿米巴样运动和转移扩散，预示黑色素瘤预后不良。
Cancers (Basel). 2020 Nov 13;12(11):3366. doi: 10.3390/cancers12113366.
8
Functional Characterization of Cholinergic Receptors in Melanoma Cells.黑色素瘤细胞中胆碱能受体的功能特性
Cancers (Basel). 2020 Oct 27;12(11):3141. doi: 10.3390/cancers12113141.
9
Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy.现代免疫治疗时代晚期黏膜黑色素瘤的多模式治疗
Cancers (Basel). 2020 Oct 26;12(11):3131. doi: 10.3390/cancers12113131.
10
Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients.黑色素瘤患者BRAF抑制剂治疗引起的关节痛
Cancers (Basel). 2020 Oct 16;12(10):3004. doi: 10.3390/cancers12103004.
Zotero 插件